Human toxoplasmosis in Mozambique: gaps in knowledge and research opportunities

Leonardo Manuel1, Gabriela Santos-Gomes2 and Emilia V. Noormahomed3,4,5*

Abstract
Toxoplasmosis is a parasitic zoonotic disease caused by *Toxoplasma gondii* that afflicts humans worldwide and wild and domestic warm-blooded animals. In immunocompetent individuals, the acute phase of infection presents transient low or mild symptoms that remain unnoticed. In immunocompromised patients, *T. gondii* is a life-threatening opportunistic infection, which can result from the reactivation of latent infection or primary infection. Moreover, congenital toxoplasmosis, which results from the transplacental passage of tachyzoites into the fetus during a pregnant primary infection, can lead to miscarriage, stillbirth, or ocular and neurologic disease, and neurocognitive deficits in the newborns. Thus, the present review aims to address the current knowledge of *T. gondii* infection and toxoplasmosis in Africa and especially in Mozambique, stressing the importance of identifying risk factors and promote awareness among the health care providers and population, assessing the gaps in knowledge and define research priorities. In Mozambique, and in general in southern African countries, clinical disease and epidemiological data have not yet been entirely addressed in addition to the implications of *T. gondii* infection in immunocompetent individuals, in pregnant women, and its relation with neuropsychiatric disorders. The main gaps in knowledge in Mozambique include lack of awareness of the disease, lack of diagnostic methods in health facilities, lack of genetic data, and lack of control strategies.

Keywords: *Toxoplasma gondii* infection, HIV-infected patients, Congenital toxoplasmosis, Ocular toxoplasmosis, Mental disorders, South east African countries, Mozambique

Background
Toxoplasmosis is a zoonotic disease caused by the parasite *Toxoplasma gondii*, a cosmopolitan intracellular protozoan. This parasite can infect a wide range of warm-blooded animals, including humans who act as intermediate hosts, supporting the asexual phase of the *T. gondii* life-cycle. Cats and wild felines have been considered definitive hosts since the sexual reproductive phase of the *T. gondii* life-cycle is restricted to these animals. People may become infected through the ingestion of raw or undercooked meat containing cyst, or by food and water contaminated with highly resistant and easily dispersed *T. gondii* oocysts from feline feces [1–3]. It seems that one to ten sporulated oocyst is enough to cause infection, giving rise to the asexual phase of the *T. gondii* life-cycle [4, 5]. Infection also can be acquired by cysts after organ transplantation and by tachyzoites, which can cross the placenta during pregnancy, causing congenital toxoplasmosis and through blood transfusion [1, 2, 6]. Globally, it is anticipated that one-third of the world population is infected with *T. gondii* and that the prevalence of infection varies between 10–80%, depending on local culture, eating habits, and climate [6–8]. In South America and tropical Africa, the prevalence of the disease is very high, with more than 50% of people infected, while in Europe, North America, and Southeast Asia the prevalence rates range from 7% to 50% [3, 9, 10]. Studies conducted in several countries of Southeast Africa,
such as Zambia, South Africa, Eswatini (former Swaziland), Zimbabwe, Angola, Namibia, Tanzania, Madagascar, Uganda, Kenya, Ethiopia, and Mozambique, indicate prevalence of *T. gondii* infection that ranges from 4% to 93% in the general population [11–13]. Signs, symptoms, and the severity of *T. gondii* infection differs according to the immune status of the individual, the age in which the infection was acquired, and the genotype of the parasite involved [2, 3, 14–16]. In immunosuppressed patients due to human immunodeficiency virus (HIV) or immunosuppressive therapy, toxoplasmosis is considered a life-threatening parasitic disease. Despite the growing numbers of drug-immunosuppressed patients and the few available studies, these patients can also be at risk of developing toxoplasmosis, in particular, the transplanted patients [17, 18]. *Toxoplasma gondii* genotyping studies recognize three major subtypes identified as subtype I, subtype II, and subtype III. Altogether they account for 95% of isolates from North America and Europe, each leading to differences in disease severity [2, 3]. In these regions, the majority of cases of congenital toxoplasmosis and toxoplasmosis infection in HIV immunosuppressed individuals are mainly caused by type II strains. However, most of the isolates from South America, Africa, and Asia do not fit into the three major lineages, except type III, which is really cosmopolitan and commonly found in animals [2, 19]. Atypical, exotic, recombinant, or non-archetypal genotypes were found in other continents and the characterization of the strains by multilocus polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), using ten genetic markers revealed 18 different genotypes. Together they account for 5% of infections, generating more virulent parasites due to its genetic diversity and the consequent increase of disease severity [3, 14, 20]. A large meta-analysis and a prospective cohort study showed a higher risk of ocular *Toxoplasmosis* in children from Brazil and Colombia than in European children (47% versus 14%). Furthermore, ocular lesions were large, numerous, and more likely to affect the retina that according to several authors may be explained by the predominance of atypical *T. gondii* strains in Latin America [21–23]. There are multiple tools available for the diagnosis of *T. gondii* infection, particularly serological, molecular, and imaging techniques. Serological assays allow the detection of *T. gondii* specific antibodies, immunoglobulin M (IgM) and immunoglobulin G (IgG). Usually, these tests possess high sensitivity and specificity due to antigen standardization and good assay reproducibility in immuno competent individuals [24]. Molecular biological tests based on polymerase chain reaction (PCR) allow detection of parasite deoxyribonucleic acid (DNA) and identification of genetic variants, while imaging techniques, such as computed tomography and magnetic resonance imaging, that have been employed to evaluate expansive brain lesions of cerebral toxoplasmosis, present high sensitivity, but low specificity and should be used in combination with other diagnostic methodologies [2, 3, 25–27]. More recently, the use of recombinant antigens has been proposed as an alternative to conventional serological assays because of its limited value, especially in immunosuppressed patients [3, 28, 29]. Patients with confirmed toxoplasmosis have multiple treatment options, depending on immune competence and disease severity. However, most of the drugs used to treat toxoplasmosis are effective against tachyzoites, the acute morphological form of *T. gondii*, but do not seem to eradicate the encysted bradyzoites forms (chronic phase). Pyrimethamine combined with sulfadiazine and trimethoprim-sulfamethoxazole combined with spiramycin are the main choice for the clinical treatment of toxoplasmosis [30]. To prevent parasite transmission from a pregnant woman to her fetus spiramycin is the drug of choice. For congenital toxoplasmosis, pyrimethamine and sulfadoxine together with folic acid to prevent bone marrow suppression are the recommended drugs to treat the newborn, while a combination of pyrimethamine, azithromycin, and corticosteroids is recommended for treating ocular toxoplasmosis [27]. Despite the limited reports available on the relative importance of toxoplasmosis in Africa and particularly in Mozambique, where the studies on human *T. gondii* infection are scarce, this review aims to: (i) summarize and critically examine the most relevant aspects of *Toxoplasma* infection and toxoplasmosis in Africa and, specifically in Mozambique; (ii) identify gaps of knowledge; (iii) highlight the research opportunities and reflect on its implications for the population well-being and for the socio-economic development of Mozambique.

**Toxoplasmosis in immunosuppressed patients**

In HIV-immunosuppressed patients and individuals undergoing cancer treatment or organ transplantation, *Toxoplasma* infection can become a severe opportunistic disease, which can result from a primary infection, but most of the time results from reactivation of an earlier acquired infection. Reactivation of bradyzoites (the dormant forms of this parasite) and differentiation in tachyzoites occurs as a consequence of patient’s reduced immunocompetence, leading to tissue injury [31, 32]. In sub-Saharan Africa, where the majority (70%) of HIV-infected people live [33], patients are commonly diagnosed with HIV after developing cerebral toxoplasmosis. It is estimate that this parasitic disease is indicative of HIV infection in 35% of patients and an acquired immunodeficiency syndrome (AIDS) defining event in 75% of the cases [3, 22, 34, 35]. With access to...
infection during pregnancy does not cause specific symp-
a limited risk of inducing a congenital infection. Primary
have acquired
T. gondii
infection before pregnancy have
reduced dramatically. Before the anti-retroviral treat-
ment era, rates of cerebral toxoplasmosis in the USA and
the UK ranged between 16 and 40%, in Brazil 50 to 80%, in France 75 to 90%, and in Spain, it was about
60% [36]. In Ethiopia, a serological study in HIV-infected
patients found Toxoplasma infections ranging from 3%
to 97% [37, 38]. In Uganda anti-T. gondii antibodies were
detected in 54% of HIV+ patients and 23% present para-
sites in the peripheral blood [39], pointing for an acute
infection that possibly represents a reactivation. On the
contrary, in Johannesburg (South Africa), the prevalence
of latent Toxoplasma infection was lower in HIV infected
patients, ranging between 8% and 18% [40, 41]. Moreo-
ver, in Nigeria, 85.5% of HIV/AIDS patients that were
under cART present latent Toxoplasma infection (sero-
positive for T. gondii IgG) and almost 40% (39.7%) exhib-
ited focal neurological signs [42]. Taken together, these
findings indicate that in the African continent, there is a
high variability T. gondii infection prevalence, which can
go from residual values to very high levels. These differ-
ces can be associated with the socioeconomic condi-
tions, including the efficacy of health systems and health
education and population traditional culture, values, cus-
toms, and beliefs.

Although several studies argued for the role of geno-
types in the clinical expression of human toxoplasmosis
and the geographical structure of Toxoplasma across
continents, genetic data concerning T. gondii isolates
from Africa are scarce. In a study performed in HIV+
patients from Uganda, the genotype II (12/22) was the
most commonly found, followed by the type I genotype
(5/22). The less representative genotypes were non-III
(3/22) and type III (2/22) [39].

Toxoplasmosis in neonates and infants
Women at risk of transmitting congenital toxoplasmo-
sis include immunocompetent women when becoming
newly infected during pregnancy or challenged with
atypical parasite strains, as well as, immunosuppressed
mothers with HIV/AIDS when the reactivation of brady-
zoites occur during pregnancy [2, 15, 43]. Women that
have acquired T. gondii infection before pregnancy have
a limited risk of inducing a congenital infection. Primary
infection during pregnancy does not cause specific symp-
toms, being unnoticed in most of the women, or lead to
some transient low to mild symptoms that usually are
not taken into consideration by the patient. In African
countries, dating Toxoplasma infection during preg-
nancy is difficult, and the use of specific serology and the
respective follow-up is often not extended to all pregnant
women [44].

According to earlier studies in southern Africa, T. gondii seroprevalence among pregnant women ranges
between 15 and 23% [39, 45, 46] and HIV-Toxoplasma
co-infection was about 8% [47]. However, in sub-Sah-
ran Africa, more recent studies among pregnant women
pointing through T. gondii-seroprevalences ranging
between 5.9% and 85.5%. [48, 49]. As a consequence of
the very high levels of T. gondii transmission among the
Nigerian population (78%), Toxoplasma infection during
pregnancy was about 30% [50, 51], representing a serious
threat for congenital infection.

The risk factors for becoming infected have been iden-
tified. Eating raw meat, unwashed fresh vegetables or
fruits, and undercooked food, drinking unpasteurized
milk, and the proximity to cats seems to be predictors of
possible infections [44]. Even so, the prevalence of Toxo-
plasma infection in pregnancy appears to be an under-
estimated public health concern in Africa, highlighting
the urgent need for further research. Furthermore, the
awareness of toxoplasmosis and its mode of transmission
among women and, in particular, pregnant women seems
to be limited [12, 52].

The risk of vertical transmission to the fetus, as a con-
sequence of crossing the placental barrier by tachyzoites,
increases during pregnancy, and about 60% to 81% of
the infections by T. gondii occur during the last trimes-
ter [2, 53]. However, the disease is more severe in the
early stages of pregnancy, depending on parasite viru-
ulence and of the infected T. gondii genotype. In the first
trimester, the rate of infection can range from 15% to
25% [10, 25, 54–57]. Congenital toxoplasmosis has been
associated with a wide range of adverse outcomes, which
includes spontaneous miscarriage, stillbirth, ocular dis-
ease, and neurologic and neurocognitive deficits. The
most frequent presentation of congenital toxoplasmosis
comprises of hydrocephalus, chorioretinitis, and cer-
bral calcifications. In up to 80% of cases, the infection
remains asymptomatic after birth, but infants may later
present mental retardation and learning and visual disa-
bilities [2, 12, 53]. In upper-middle-income countries, the
incidence of congenital hydrocephalus is at 0.5 cases per
1000 live births, whereas in Africa and Latin America the
incidence of neonatal hydrocephalus was estimated to be
around 145 and 316 per 100.000 births, respectively [58,
59]. In Nigeria it was determined that abortion occurred
in 41.6% to 60% of pregnant women presenting anti-Toxo-
plasma antibodies, stillbirth happened in 6.8% to 61.5%
of the cases, and neonatal death in 62.5%. Ocular prob-
lems occurred in 29.4% of newborns [60–62]. Torgerson
and Mastroiacovo [63] estimated per 1000 live births the
incidence of congenital cases accounting for 2–2.4 to
13–15 of all Disability-Adjusted Life Years (DALYs) for
the African continent, despite several African countries
have not reported cases of congenital toxoplasmosis or seroprevalence data. Infants can also acquire primary *Toxoplasma* infection after birth and develop severe disease [3, 35, 64].

In a recent study in Tunisia, *T. gondii* isolated from the amniotic fluid and placenta of women that had an acute infection during pregnancy was revealed to be of the type II genotype [65]. However, no other published studies on *T. gondii* genotypes occurring on the African continent were found, especially in sub-Saharan African countries.

**Toxoplasma infection in immunocompetent patients**

Studies conducted in immunocompetent individuals living in European countries or North America found that primarily acquired *T. gondii* infection is asymptomatic and self-limited in more than 80% of individuals [3, 66]. In a few cases, patients may present fever or cervical lymphadenopathy, sometimes associated with myalgia, asthenia, or other non-specific clinical signs that can be misdiagnosed with different clinical conditions, exhibiting similar symptoms. The knowledge of the neuropathology caused by *Toxoplasma* is progressing. [3, 57, 67–69]. The immune response of chronically infected patients is mainly characterized by interferon-γ production which induces the activation of indoleamine-2,3-dioxygenase leading to tryptophan (amino acid essential for serotonin biosynthesis) depletion, increase of kynurenine acid, and decrease of serotonin. Moreover, high tyrosine hydrolase activity directs dopamine release. Thus, high levels of kynurenine acid and dopamine, along with low amounts of serotonin are associated with cognitive dysfunctions [3].

Schizophrenia is a serious psychiatric disorder with a lifetime prevalence of approximately 1% and is rated as the 9th most common cause of disability all over the world [67]. Since 1953, more than 19 studies were done in patients with schizophrenia and other severe psychiatric disorders, testing for antibodies against *T. gondii*. Of these, 18 studies found patients with a higher frequency of anti-*T. gondii* antibodies, and in 11 out of 18, the association was statistically significant [57]. These conditions are indicated as the leading cause of disability in the world, accounting for 22.7% of DALYs [69].

A systematic review on the relationship between *Toxoplasma* infection and epilepsy concluded that this parasitic infection should be an epilepsy risk factor and that there is a need to conduct more studies to determine the real impact of *T. gondii* infection on epilepsy [70, 71]. Moreover, studies conducted in Turkey and USA, in patients with cryptogenic epilepsy which aimed to evaluate its possible relationship with *T. gondii* found 54% and 75% of these patients infected with *Toxoplasma*, respectively [72, 73].

In Southeast Africa, there is a scarcity of studies aiming to define the relationship between epilepsy and *Toxoplasma* infection. A multicenter study conducted in Kenya, South Africa, Uganda, Tanzania, and Ghana in a total of 1711 individuals with active convulsive epilepsy found an odds ratio of 1.39 with previous exposure to *T. gondii* [74]. Moreover, studies from Kenya and other African countries concluded that in addition to *Toxoplasma* infection, malaria, onchocerciasis, neurocysticercosis, and toxocariasis also might be involved in the pathogenesis of epilepsy [75, 76]. There is also evidence of possible association with some neurodegenerative disorders, such as Parkinson and Alzheimer diseases, in which the prevalence of *Toxoplasma* infection is around 85% and 66%, respectively [3, 77–81]. Suicidal behaviour is also a common problem in southeast Africa. A study from South Africa found that 3.2% of adolescents attempted to commit suicide, 5.8% planned, and 7.2 reported ideation [82]. In Zambia, acute psychotic syndrome is the most common outpatient diagnosis, followed by schizophrenia, substance use disorder, and dementia [83]. Although *T. gondii* infection was considered a potential risk factor for suicide attempts [84], no studies exist reporting possible links between suicide attempts and *Toxoplasma* infection in Africa.

**Burden of pathological disorders related possibly to Toxoplasma infection in Mozambique**

Mozambique is a low-income country located in Southeast Africa, with 28.8 million people, a child mortality rate of 57.9‰, an adult literacy rate of 60.7%, and with most of the population (about 66%) living in rural areas [85]. According to the United Nations Development Programme [86], this country ranks 180th on the human development index, which points towards a high unmeet in health care performance, low education levels, and basic living standards [87]. The national health system covers only 50% of the population, and according to the Mozambique Poverty Reduction Action Plan 2011–2014 [88] 65% of the population have access to a health unit facility within 45 min walking distance of their homes. Despite natural fluctuations according to geographical settings, tuberculosis, HIV, malaria, neglected tropical diseases, in addition to respiratory and diarrheal diseases, still are significant causes of morbidity and mortality in Mozambique and among Southeastern African countries [87, 89–91]. Furthermore, non-infectious diseases, including cardiovascular diseases, cancer, chronic respiratory diseases, and diabetes also accounts for disease burden in Mozambique [92].
In 2018, the prevalence of HIV in Mozambique was 12.6% in the age group of 15 to 49 years-old and 45,000 AIDS deaths [93], with nearly 2.2 million people living with HIV infection [94, 95]. Together with some of the neighboring countries, such as Eswatini, South Africa, Zimbabwe, Zambia, Malawi, and Tanzania, Mozambique is among the top ten countries presenting the highest prevalence of HIV in the world, which ranges from 6.5% to 27.2% [91].

Toxoplasma gondii infection can also be related to mental disorders in immunocompetent individuals and in immunocompromised patients, in addition to the neuropsychiatric disorders of congenital toxoplasmosis. There was a significant improvement in the Mozambique mental health services, reaching rates of 0.59 mental health out-patient facilities and 0.09 psychiatric hospitals for 100,000 persons [96]. Mozambique has a suicide rate of 4.9 and a total of 1412 suicides per year, being in the 134 position in the global suicide rank [97]. However, this country has no published national suicide statistics. Even so, a cross-sectional study performed in unnatural death, recorded from 2000–2009 at the Forensic Services in Maputo Central Hospital, reported 9% of suicide [98]. Epilepsy affects 50 million people worldwide, and about 80% live in low-income countries [99]. According to a previous study, Mozambique has a prevalence of 1.6% for epilepsy, pointing out to more than 400,000 individuals living with epilepsy [100]. However, most of these patients seemed to be children and adolescents [101]. Hydrocephalus is a serious problem in sub-Saharan Africa and despite there is little information about this disorder, it was predicted that in Mozambique an incidence of 2900 to 4800 cases of neonatal hydrocephalus occur per year [102]. Despite the high rates of HIV infection in Southeast Africa, including Mozambique, the high incidence of hydrocephalus in sub-Saharan Africa and Mozambique, and the high prevalence of mental disorders, Toxoplasma infection still is overlooked in Mozambique. According to the International Agency for the Prevention of Blindness [103] in Mozambique, sight disease affects more than 300,000 persons from Maputo (capital of Mozambique) and Inhambane province, most of the cases are reported as cataract, glaucoma, and trachoma. Despite these numbers, there is no study or report about the incidence of ocular toxoplasmosis in Mozambique.

Though, little is known about the burden of toxoplasmosis in Southeastern Africa and Mozambique. In particular, the identification of risk factors, the genetic diversity of the parasite, as well as, Toxoplasma association with HIV, was not examined, the incidence of Toxoplasma infection in pregnant women, and the relationship with hydrocephalus and neuropsychiatric disorders, such as epilepsy, schizophrenia, suicidal behaviors, mood disorders, obsessive-compulsive disorder, and generalized anxiety [104] among other conditions, was not examined.

Toxoplasma infection in Mozambique

Although T. gondii is commonly associated with immunodeficiency disorders, a limited number of studies have been performed in Africa and, to the best of our knowledge, nobody has previously investigated the risk of reactivation of latent T. gondii infection in Mozambique HIV+ patients, for example. However, in the last decade a cross-sectional study in HIV+/AIDS patients performed in Maputo (Mozambique) found a 46% prevalence of anti-Toxoplasma IgG, pointing towards a latent Toxoplasma infection among almost half of HIV+/AIDS patients. This study also identified the regular consumption of cattle meat, breeding cats and dogs, and regular contact with the soil as risk factors to acquire Toxoplasma infection [11]. Another study aiming to assess clinic-pathological discrepancies in the diagnosis of causes of death in HIV infected adults from Mozambique found that none of the 8/73 (9.6%) cases of toxoplasmosis confirmed in the autopsy were clinically suspected, indicating 100% of major clinical discrepancies [105] (Fig. 1).

Congenital toxoplasmosis can cause miscarriage, blindness, deafness, hydrocephalus, and brain damage. Newborns may appear healthy at birth, but later in life can suffer from eye diseases, or have cognitive difficulties. Moreover, screening of Toxoplasma infection during pregnancy and specific treatment resulted in a decrease of T. gondii transmission from mother to child and a consequent reduction of clinical sequelae in infants [43]. There are no published data on the burden of congenital toxoplasmosis in Mozambique, nor its relation with hydrocephalus, seizures and mental retardation, which are disorders prevalent in Mozambique as already referred. A previous study performed by Sitoe et al. [106] in 150 pregnant women seeking the first trimester prenatal care in Maputo Central Hospital (Maputo, Mozambique) reported an overall prevalence of 18.7% of Toxoplasma IgG antibodies with the occurrence of 31.3% in HIV+ pregnant women and 10.9% in immunocompetent pregnant women (Fig. 1). Taking into account the dimension of this study, the findings indicate the less than 25% of the pregnant woman had previous contact with T. gondii and that part of these women were Toxoplasma/HIV co-infected. In the same study, only one woman presenting significant levels of anti-Toxoplasma IgM was found [106], pointing towards a lower occurrence of active T. gondii infection during the first trimester of pregnancy in Maputo. The incidence of neonatal hydrocephalus in Mozambique was estimated to be 3–5 cases per 1000 live births [102], which leads to severe
disability as is a significant cause of morbidity and mortality. However, the proportion of children that acquired *T. gondii* infection during pregnancy and developed congenital toxoplasmosis is not known. Similarly, there are no studies available on the importance of *T. gondii* infection in ocular disease, mental retardation, schizophrenia and epilepsy either in children or in adults living in Mozambique.

Moreover, in Mozambique, there are no available data on the clinical expression and severity of human toxoplasmosis in the diverse segments of the population and across the different regions, identification of *T. gondii* strains that circulate in the country, and on the dynamics of parasite transmission.
Conclusions

Toxoplasma gondii is a globally widespread parasite that invades and chronically persists in the central nervous system of infected individuals. The complexity of this infection is a consequence of the intimate relationship established between the parasite and the host immunity, which can lead to persistent infections of limited pathogenesis. Further advances in the understanding of Toxoplasma infection have found a link between this parasite, mental and mood disorders, and suicidal behavior. However, this parasitic infection should not be evaluated from a restricted anthropogenic perspective since wild and domestic animals are involved in parasite genetic recombination and transmission. Moreover, molecular studies contributed to identifying different parasite strains associated with virulence levels and implicated in the specific clinical characteristics of the disease. Thus, it is of utmost importance to estimate the incidence of T. gondii infection and toxoplasmosis among the Mozambique population. The few available studies reflect the reality of Maputo, the Mozambique capital, and comprehensive information for the entire country is missing. Furthermore, understanding the extension of T. gondii infection and the risk factors associated is a pre-requisite for the development of effective control measures. Then, it is urgent to develop and implement research programs directed to the gaps of knowledge, which include up-to-date information on T. gondii geographical distribution, the incidence and risk factors of immunocompetent, congenital, and perinatal infection, the occurrence of ocular toxoplasmosis, the association of Toxoplasma infection with mental and neurodegenerative disorders, as well as the identification of T. gondii genotypes circulating in Mozambique and its relation to morbidity and mortality. The research priorities identified for Mozambique can be an excellent starting point to inspire neighboring eastern African countries to foster research, in particular on this parasitic infection, and thus increasing knowledge in scientific and clinical areas, promoting the reduction of social impacts related to disability and consequent labor hours lost and advance the social-economic conditions.

Abbreviations
AIDS: acquired immunodeficiency syndrome; DNA: deoxyribonucleic acid; HIV: human immunodeficiency virus; PCR-RFLP: polymerase chain reaction-restriction fragment length polymorphism; IgG: immunoglobulin G; IgM: immunoglobulin M; PCR: polymerase chain reaction; CART: combination antiretroviral therapy; DALYs: Disability-adjusted life years.

Acknowledgements
The authors are grateful to Professor Virgilio do Rosário, retired Professor from Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, for his mentorship during the manuscript writing.

Authors’ contributions
LM performed the literature review and was a major contributor in writing the manuscript, GG and EVN conceptualized, and revised the manuscript. All authors read and approved the final manuscript.

Funding
The research work and student fellowship were supported by the Grant D43TW010568-02, titled Enhanced Advanced Biomedical Research Training in Mozambique from the National Institutes of Health (NIH)- Fogarty International Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Fogarty International Center or the National Institutes of Health.

Availability of data and materials
Not applicable.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1. Faculty of Health Sciences, Universidade Lurio, Nampula, Mozambique.
2. Global Health and Tropical Medicine (GHTM), Instituto de Higiene e Medicina Tropical (IHMT), Universidade Nova de Lisboa (UNL), Lisbon, Portugal.
3. Department of Microbiology, Faculty of Medicine, Universidade Eduardo Mondlane (UEM), Maputo, Mozambique. 4 Department of Medicine, Infectious Disease Division, University of California, San Diego, USA. 5 Mozambique Institute for Health Education and Research (MIHER), Maputo, Mozambique.

Received: 11 August 2020 Accepted: 30 October 2020 Published online: 11 November 2020

References
1. Ajzenberg D, Lamaury I, Demar M, Vautrin C, Cabie A, Simon S, et al. Performance testing of PCR assay in blood samples for the diagnosis of toxoplasmic encephalitis in AIDS patients from the French departments of America and genetic diversity of Toxoplasma gondii: a prospective and multicentric study. PLoS Negl Trop Dis. 2016;10:e0004790.
2. Bruggmann D, Handl V, Klingelhofer D, Jaque J, Gornege DA. Congenital toxoplasmosis: an in-depth density-equalizing mapping analysis to explore its global research architecture. Parasit Vectors. 2015;8:646.
3. Xiao J, Prandovszky E, Kannan G, Pletnikov MV, Dickerson F, Severance EG, et al. Toxoplasma gondii: biological parameters of the connection to schizophrenia. Schizophr Bull. 2018;44:983–92.
4. Dubey JP. Toxoplasma gondii infections in chickens (Gallus domesticus): prevalence, clinical disease, diagnosis and public health significance. Zoonoses Public Health. 2010;57:60–73.
5. Petersen E, Vesco G, Villari S, Bufofano W. What do we know about risk factors for infection in humans with Toxoplasma gondii and how can we prevent infections? Zoonoses Public Health. 2010;57:8–17.
6. Laboudi M. Review of toxoplasmosis in Morocco: seroprevalence and risk factors for Toxoplasma infection among pregnant women and HIV-infected patients. Pan Afr Med J. 2017;27:269.
7. Pan M, Lyu C, Zhao J, Shen B. Sixty years (1957–2017) of research on toxoplasmosis in China—an overview. Front Microbiol. 2017;8:1825.
8. Samojlowicz D, Twarowska-Malczynska J, Borowska-Solonycka A, Poniatowski LA, Sharma N, Oliczak M. Presence of Toxoplasma gondii infection in brain as a potential cause of risky behavior: a report of 102 autopsy cases. Eur J Clin Microbiol Infect Dis. 2019;38:305–17.
9. Prusa AR, Kasper DC, Olischar M, Husslein P, Pollak A, Hayde M. Evaluation of serological prenatal screening to detect Toxoplasma gondii infections in Austria. Neonatology. 2013;103:27–34.
98. Francisco V, Silveira J, Zacarias A. Suicide in Mozambique: evidence from 10 years mortality data from forensic services at Maputo Central Hospital, Maputo city. Injury Prev. 2012;18:A166.
99. WHO. Epilepsy. 2019. Geneva: World Health Organization; 2019. https://www.who.int/news-room/fact-sheets/detail/epilepsy. Accessed 15 July 2020.
100. Patel V, Simbine AP, Soares IC, Weiss HA, Wheeler E. Prevalence of severe mental and neurological disorders in Mozambique: a population-based survey. Lancet. 2007;370:1055–60.
101. Dos Santos PF, Cumbe V, Gouveia ML, de Fouchier C, Teuwen D, Dua T. Implementation of mhGAP in Mozambique: integrating epilepsy care into the primary health care system. Int J Ment Health Syst. 2019;13:36.
102. Salvador SF, Henriques JC, Munguambe M, Vaz RM, Barros HP. Hydrocephalus in children less than 1 year of age in northern Mozambique. Surg Neurol Int. 2014;5:175.
103. International Agency for the Prevention of Blindness. The IAPB vision atlas. https://atlas.iapb.org/about-vision-atlas/. Accessed 15 July 2020.
104. Markovitz AA, Simanek AM, Yolken RH, Galea S, Koenen KC, Chen S, et al. Toxoplasma gondii and anxiety disorders in a community-based sample. Brain Behav Immun. 2015;43:192–7.
105. Ordi J, Castillo P, Garcia-Basteiro AL, Moraleta C, Fernandes F, Quinto L, et al. Clinico-pathological discrepancies in the diagnosis of causes of death in adults in Mozambique: a retrospective observational study. PLoS ONE. 2019;14:e0220657.
106. Sitoe SP, Rafael B, Meireles LR, Andrade HF Jr, Thompson R. Preliminary report of HIV and Toxoplasma gondii occurrence in pregnant women from Mozambique. Rev Inst Med Trop Sao Paulo. 2010;52:291–5.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.